Concert Pharmaceuticals Inc. (NASDAQ:CNCE)’s share price was down 2.5% during mid-day trading on Friday . The company traded as low as $11.21 and last traded at $11.47, with a volume of 56,462 shares. The stock had previously closed at $11.77.

A number of equities analysts have issued reports on CNCE shares. Brean Capital restated a “buy” rating on shares of Concert Pharmaceuticals in a research report on Saturday, April 30th. Stifel Nicolaus started coverage on shares of Concert Pharmaceuticals in a research report on Friday, July 1st. They set a “buy” rating and a $23.00 target price for the company. Finally, Zacks Investment Research upgraded shares of Concert Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, May 17th. Two investment analysts have rated the stock with a sell rating and six have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $26.43.

The firm’s 50-day moving average price is $11.52 and its 200-day moving average price is $13.11. The stock has a market capitalization of $255.26 million and a price-to-earnings ratio of 13.79.

Concert Pharmaceuticals (NASDAQ:CNCE) last released its quarterly earnings results on Thursday, May 5th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.45) by $0.18. On average, equities research analysts forecast that Concert Pharmaceuticals Inc. will post ($2.16) EPS for the current year.

In other news, CEO Roger D. Tung purchased 19,610 shares of the stock in a transaction dated Wednesday, May 11th. The stock was acquired at an average price of $10.55 per share, for a total transaction of $206,885.50. Following the completion of the transaction, the chief executive officer now owns 538,965 shares of the company’s stock, valued at $5,686,080.75. The purchase was disclosed in a filing with the SEC, which is available at the SEC website.

A hedge fund recently raised its stake in Concert Pharmaceuticals stock. Dimensional Fund Advisors LP raised its stake in shares of Concert Pharmaceuticals Inc. (NASDAQ:CNCE) by 405.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 224,348 shares of the company’s stock after buying an additional 179,998 shares during the period. Dimensional Fund Advisors LP owned 1.02% of Concert Pharmaceuticals worth $4,256,000 at the end of the most recent quarter.

Concert Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others segment. It has clinical candidates under development, including AVP-786, CTP-656, CTP-730 and JZP-386.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.